Cowen raised its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $117.00 (from $93.00) while ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Alnylam Pharmaceuticals (ALNY) PT Raised to $134 at BMO Capital; Makes Case for $165 Upside ScenarioSeptember 21, 2017 3:40 PM Alnylam Pharmaceuticals (ALNY) PT Raised to $101 at Morgan StanleySeptember 21, 2017 8:37 AM Alnylam Pharmaceuticals (ALNY) PT Raised to $135 at BernsteinSeptember 21, 2017 7:23 AM UPDATE: Alnylam Pharmaceuticals (ALNY) PT Raised to $146 at Ladenburg ThalmannSeptember 21, 2017 7:04 AM Alnylam Pharmaceuticals (ALNY) PT Raised to $123 at Credit SuisseSeptember 21, 2017 6:26 AM Alnylam Pharmaceuticals (ALNY) PT Raised to $125 at Needham & CompanySeptember 20, 2017 3:20 PM Alnylam Pharmaceuticals (ALNY) PT Raised to $128 at JMP SecuritiesSeptember 20, 2017 2:14 PM Alnylam Pharmaceuticals (ALNY) PT Raised to $83 at StifelSeptember 20, 2017 1:41 PM Arbutus Biopharma (ABUS) and Alnylam Pharmaceuticals, Inc. (ALNY) Reports Positive Phase 3 Results for LNP-Enabled Patisiran ProgramSeptember 20, 2017 12:25 PM Arbutus’ LNP Licensee Alnylam Announces Positive Phase 3 Results for LNP-Enabled Patisiran ProgramSeptember 20, 2017 12:22 PM Alnylam Pharmaceuticals (ALNY) PT Raised to $116 at Piper JaffraySeptember 20, 2017 11:39 AM Alnylam Pharma (ALNY) Adds to Gains; Shares up 40%September 20, 2017 10:23 AM Royalty Stream to Arbutus Biopharma (ABUS) from Alnylam (ALNY) 'Could be Significant' - WedbushSeptember 20, 2017 10:19 AM Arbutus Biopharma (ABUS) Gains Sharply Following Alnylam Trial SuccessSeptember 20, 2017 10:12 AM Pre-Open Stock Movers 09/20: (ALNY) (KPTI) (GEMP) Higher; (BBBY) (IONS) (GIS) Lower (more...)September 20, 2017 9:29 AM Alnylam Pharma (ALNY) Gains 22% on Patisiran Phase 3 Trial SuccessSeptember 20, 2017 7:53 AM Ionis Pharma (IONS) Sinks on Alnylam (ALNY) Patisiran SuccessSeptember 20, 2017 7:36 AM Sanofi, Alnylam Pharmaceuticals (ALNY) Announces APOLLO Phase 3 Study of Patisiran Met Primary Efficacy Endpoint and All Secondary EndpointsSeptember 20, 2017 7:02 AM Sanofi (SNY) and Alnylam (ALNY) APOLLO Phase 3 Study of Patisiran in hATTR Meets Primary, Secondary EndpointsSeptember 20, 2017 7:01 AM Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with PolyneuropathySeptember 20, 2017 7:00 AM